Alana A Lewis1, Colby R Ayers1, Elizabeth Selvin2, Ian Neeland1, Christie M Ballantyne3, Vijay Nambi3,4,5, Ambarish Pandey1, Tiffany M Powell-Wiley6, Mark H Drazner1, Mercedes R Carnethon7, Jarett D Berry1, Stephen L Seliger8, Christopher R DeFilippi9, James A de Lemos1. 1. Department of Medicine, University of Texas Southwestern Medical Center, Dallas (A.A.L., C.R.A., I.N., A.P., M.H.D., J.D.B., J.A.d.L.). 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (E.S.). 3. Department of Medicine, Baylor College of Medicine, Houston, TX (C.M.B., V.N.). 4. Houston Methodist DeBakey Heart and Vascular Center, TX (V.N.). 5. Department of Medicine, Michael E. DeBakey Veterans Affairs Hospital, Houston, TX (V.N.). 6. Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (T.M.P.-W.). 7. Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (M.R.C.). 8. Department of Medicine, University of Maryland School of Medicine, Baltimore (S.L.S.). 9. Inova Heart and Vascular Institute, Falls Church, VA (C.R.d.F.).
Abstract
BACKGROUND: A malignant subphenotype of left ventricular hypertrophy (LVH) has been described, in which minimal elevations in cardiac biomarkers identify individuals with LVH at high risk for developing heart failure (HF). We tested the hypothesis that a higher prevalence of malignant LVH among blacks may contribute to racial disparities in HF risk. METHODS: Participants (n=15 710) without prevalent cardiovascular disease were pooled from 3 population-based cohort studies, the ARIC Study (Atherosclerosis Risk in Communities), the DHS (Dallas Heart Study), and the MESA (Multi-Ethnic Study of Atherosclerosis). Participants were classified into 3 groups: those without ECG-LVH, those with ECG-LVH and normal biomarkers (hs-cTnT (high sensitivity cardiac troponin-T) <6 ng/L and NT-proBNP (N-terminal pro-B-type natriuretic peptide) <100 pg/mL), and those with ECG-LVH and abnormal levels of either biomarker (malignant LVH). The outcome was incident HF. RESULTS: Over the 10-year follow-up period, HF occurred in 512 (3.3%) participants, with 5.2% in black men, 3.8% in white men, 3.2% in black women, and 2.2% in white women. The prevalence of malignant LVH was 3-fold higher among black men and women versus white men and women. Compared with participants without LVH, the adjusted hazard ratio for HF was 2.8 (95% CI, 2.1-3.5) in those with malignant LVH and 0.9 (95% CI, 0.6-1.5) in those with LVH and normal biomarkers, with similar findings in each race/sex subgroup. Mediation analyses indicated that 33% of excess hazard for HF among black men and 11% of the excess hazard among black women was explained by the higher prevalence of malignant LVH in blacks. Of black men who developed HF, 30.8% had malignant LVH at baseline, with a corresponding population attributable fraction of 0.21. The proportion of HF cases occurring among those with malignant LVH, and the corresponding population attributable fraction, were intermediate and similar among black women and white men and lowest among white women. CONCLUSIONS: A higher prevalence of malignant LVH may in part explain the higher risk of HF among blacks versus whites. Strategies to prevent development or attenuate risk associated with malignant LVH should be investigated as a strategy to lower HF risk and mitigate racial disparities.
BACKGROUND: A malignant subphenotype of left ventricular hypertrophy (LVH) has been described, in which minimal elevations in cardiac biomarkers identify individuals with LVH at high risk for developing heart failure (HF). We tested the hypothesis that a higher prevalence of malignant LVH among blacks may contribute to racial disparities in HF risk. METHODS:Participants (n=15 710) without prevalent cardiovascular disease were pooled from 3 population-based cohort studies, the ARIC Study (Atherosclerosis Risk in Communities), the DHS (Dallas Heart Study), and the MESA (Multi-Ethnic Study of Atherosclerosis). Participants were classified into 3 groups: those without ECG-LVH, those with ECG-LVH and normal biomarkers (hs-cTnT (high sensitivity cardiac troponin-T) <6 ng/L and NT-proBNP (N-terminal pro-B-type natriuretic peptide) <100 pg/mL), and those with ECG-LVH and abnormal levels of either biomarker (malignant LVH). The outcome was incident HF. RESULTS: Over the 10-year follow-up period, HF occurred in 512 (3.3%) participants, with 5.2% in black men, 3.8% in white men, 3.2% in black women, and 2.2% in white women. The prevalence of malignant LVH was 3-fold higher among black men and women versus white men and women. Compared with participants without LVH, the adjusted hazard ratio for HF was 2.8 (95% CI, 2.1-3.5) in those with malignant LVH and 0.9 (95% CI, 0.6-1.5) in those with LVH and normal biomarkers, with similar findings in each race/sex subgroup. Mediation analyses indicated that 33% of excess hazard for HF among black men and 11% of the excess hazard among black women was explained by the higher prevalence of malignant LVH in blacks. Of black men who developed HF, 30.8% had malignant LVH at baseline, with a corresponding population attributable fraction of 0.21. The proportion of HF cases occurring among those with malignant LVH, and the corresponding population attributable fraction, were intermediate and similar among black women and white men and lowest among white women. CONCLUSIONS: A higher prevalence of malignant LVH may in part explain the higher risk of HF among blacks versus whites. Strategies to prevent development or attenuate risk associated with malignant LVH should be investigated as a strategy to lower HF risk and mitigate racial disparities.
Authors: Sophie E Claudel; Joel Adu-Brimpong; Alnesha Banks; Colby Ayers; Michelle A Albert; Sandeep R Das; James A de Lemos; Tammy Leonard; Ian J Neeland; Joshua P Rivers; Tiffany M Powell-Wiley Journal: Am Heart J Date: 2018-08-06 Impact factor: 4.749
Authors: Aya J Alame; Sonia Garg; Julia Kozlitina; Colby Ayers; Ronald M Peshock; Susan A Matulevicius; Mark H Drazner Journal: JAMA Cardiol Date: 2018-12-01 Impact factor: 14.676
Authors: Shunsuke Natori; Shenghan Lai; J Paul Finn; Antoinette S Gomes; W Gregory Hundley; Michael Jerosch-Herold; Gregory Pearson; Shantanu Sinha; Andrew Arai; Joao A C Lima; David A Bluemke Journal: AJR Am J Roentgenol Date: 2006-06 Impact factor: 3.959
Authors: Stephen L Seliger; James de Lemos; Ian J Neeland; Robert Christenson; John Gottdiener; Mark H Drazner; Jarett Berry; John Sorkin; Christopher deFilippi Journal: JACC Heart Fail Date: 2015-05-14 Impact factor: 12.035
Authors: Lloyd E Chambless; Aaron R Folsom; A Richey Sharrett; Paul Sorlie; David Couper; Moyses Szklo; F Javier Nieto Journal: J Clin Epidemiol Date: 2003-09 Impact factor: 6.437
Authors: Ian J Neeland; Mark H Drazner; Jarett D Berry; Colby R Ayers; Christopher deFilippi; Stephen L Seliger; Vijay Nambi; Darren K McGuire; Torbjørn Omland; James A de Lemos Journal: J Am Coll Cardiol Date: 2012-12-05 Impact factor: 24.094
Authors: Anderson C Armstrong; Ola Gjesdal; André Almeida; Marcelo Nacif; Colin Wu; David A Bluemke; Lyndia Brumback; João A C Lima Journal: Echocardiography Date: 2013-08-10 Impact factor: 1.724
Authors: Orlando M Gutiérrez; Sophie Limou; Feng Lin; Carmen A Peralta; Holly J Kramer; J Jeffrey Carr; Kirsten Bibbins-Domingo; Cheryl A Winkler; Cora E Lewis; Jeffrey B Kopp Journal: Kidney Int Date: 2017-10-14 Impact factor: 18.998
Authors: Daniel Pan; Shirley Sze; Jatinder S Minhas; Mansoor N Bangash; Nilesh Pareek; Pip Divall; Caroline Ml Williams; Marco R Oggioni; Iain B Squire; Laura B Nellums; Wasim Hanif; Kamlesh Khunti; Manish Pareek Journal: EClinicalMedicine Date: 2020-06-03
Authors: Samuel T Savitz; Thomas Leong; Sue Hee Sung; Keane Lee; Jamal S Rana; Grace Tabada; Alan S Go Journal: J Am Heart Assoc Date: 2021-01-21 Impact factor: 5.501
Authors: Venkatesh L Murthy; Ravi V Shah; Jared P Reis; Alexander R Pico; Robert Kitchen; Joao A C Lima; Donald Lloyd-Jones; Norrina B Allen; Mercedes Carnethon; Gregory D Lewis; Matthew Nayor; Ramachandran S Vasan; Jane E Freedman; Clary B Clish Journal: Circulation Date: 2020-10-19 Impact factor: 29.690
Authors: Neela D Thangada; Kershaw V Patel; Bradley Peden; Vijay Agusala; Julia Kozlitina; Sonia Garg; Mark H Drazner; Colby Ayers; Jarett D Berry; Ambarish Pandey Journal: J Am Heart Assoc Date: 2021-02-22 Impact factor: 5.501